Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN
RT @vasculitides: Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
RT @vasculitides: Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
RT @vasculitides: Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
RT @vasculitides: Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
RT @vasculitides: Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
Tocilizumab for giant cell arteritis - Review - Cochrane Database Syst Rev https://t.co/i1pB8Co7po
What are the benefits and risks of tocilizumab (a medicine that reduces inflammation) for treating giant cell arteritis (a disease of the blood vessels)? https://t.co/EdEgWj21L9
8-22-2021: In a meta-analysis released today from Grand Rapids, Michigan, and Denver, Colorado that included only 2 clinical trials, Actemra (tocilizumab) performed well in treating patients with Giant Cell Arteritis: https://t.co/5vaLlQPcVB https://t.co/